Nuveen’s Indivior Pharmaceuticals INDV Stock Holding History

Nuveen’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.4M	Sell	930,911 -6,791	-0.7%	-$224K	0.01%	936
2025 Q4	$33.6M	Buy	937,702 +78,057	+9%	+$2.38M	0.01%	842
2025 Q3	$20.7M	Buy	859,645 +517,402	+151%	+$10.8M	0.01%	1126
2025 Q2	$5.05M	Buy	342,243 +257,519	+304%	+$3M	﹤0.01%	1878
2025 Q1	$793K	Sell	84,724 -8,035	-9%	-$84.5K	﹤0.01%	2741
2024 Q4	$1.19M	Hold	92,759	–	–	﹤0.01%	2638
2024 Q3	$916K	Hold	92,759	–	–	﹤0.01%	2800
2024 Q2	$1.45M	Hold	92,759	–	–	﹤0.01%	2540
2024 Q1	$1.98M	Sell	92,759 -5,741	-6%	-$108K	﹤0.01%	2409
2023 Q4	$1.49M	Buy	+98,500	New	+$1.75M	﹤0.01%	2549

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen's INDV Position: Q1 2026 in Review

Nuveen reduced its Indivior Pharmaceuticals (INDV) stake by 0.72% in Q1 2026, selling an estimated $224K and leaving 930,911 shares worth $28.4M. The position accounts for 0.01% of the portfolio, ranked #936.

Nuveen first reported a position in INDV in Q4 2023 and has held it in 10 quarters since. The position peaked at $33.6M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

Nuveen held 930,911 shares of Indivior Pharmaceuticals worth $28.4M as of Q1 2026.
Nuveen sold 6,791 Indivior Pharmaceuticals shares in Q1 2026, an estimated $224K.
Indivior Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q1 2026, its #936 holding.
Nuveen first reported a position in Indivior Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Nuveen's Indivior Pharmaceuticals position peaked at $33.6M in Q4 2025.
289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.